Dr. Rajiv Agarwal is a practicing nephrologist and a tenured Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN. Dr. Agarwal earned his medical degree from the All India Institute of Medical Sciences in New Delhi. After completing residency in Internal Medicine at the same institution he completed a Nephrology fellowship at University of Texas, Southwestern Dallas. Dr. Agarwal has published ~ 350 original papers and reviews in Nephrology. He has had numerous invited lectures including those from national societies such as National Kidney Foundation, American Society Nephrology, International Society of Nephrology, European Dialysis and Transplant Association, and the American Heart Association. Dr. Agarwal has received the Indiana University Trustee's teaching award and the young scholar award of the American Society of Hypertension. He serves or has served on the Editorial Boards of numerous journals such as Kidney International, CJASN, Hypertension and Seminars in Dialysis and he is currently an Editor for Nephrology Dialysis Transplantation, and the American Journal of Nephrology. In the past he served as an editor for the Journal of the American Society of Hypertension and NephSAP.

Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. His foremost contribution has been in the area of hypertension in hemodialysis patients. He has been funded continuously since 2003 by the National Institutes of Health. He has refined the techniques to diagnose and treat hypertension in this complex group of patients and performed important randomized trials in this difficult group of patients. He has served on the Board of Directors of KDIGO, as a panelist for Medical Evidence Development Coverage Advisory Committee (MEDCAC) for United States Medicare, co-edited a textbook of hypertension in chronic kidney disease and is a recipient of the Clinical Excellence award from the American Nephrologists of Indian Origin (ANIO). He has chaired several kidney event adjudication committees for large randomized clinical trials including CREDENCE, SONAR, BEACON, FIGARO, and FIDELIO and served as the chair of a core group lead by the International Society of Nephrology (ISN) to standardize the definitions of kidney failure for use in clinical trials worldwide.